Dual Anti-HER2 Therapy (Lapatinib and Trastuzumab) Plus Chemotherapy in HER2-positive MBC
To explore the real world situation of trastuzumab and lapatinib combined chemotherapy in China, and to explore the relationship between progression free survival and treatment.
Breast Cancer
PFS, Progression free survival, 6 weeks|OS, Overall survival, 6 weeks|ORR, Objective Response Rate, 6 weeks
Treatment Pattern, Choice of Treatment, 6 weeks
To explore the real world situation of trastuzumab and lapatinib combined chemotherapy in China, and to explore the relationship between progression free survival and treatment.